- Home
- TECX
as of 09-01-2026 10:28am EST
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 618.9M | IPO Year: | 2018 |
| Target Price: | $75.20 | AVG Volume (30 days): | 209.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | semi-annual |
| EPS: | -2.52 | EPS Growth: | 40.70 |
| 52 Week Low/High: | $14.38 - $39.53 | Next Earning Date: | 05-07-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -11.88 | Index: | N/A |
| Free Cash Flow: | -60286000.0 | FCF Growth: | N/A |
AI-Powered TECX Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Tectonic Therapeutic Inc. (TECX)
Chief Scientific Officer
Avg Cost/Share
$36.52
Shares
43
Total Value
$1,570.36
Owned After
55,285
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| McNamara Peter | TECX | Chief Scientific Officer | Aug 25, 2026 | Sell | $36.52 | 43 | $1,570.36 | 55,285 |
Earnings Transcripts
SEC 8-K filings with transcript text
2026 Q2 Q2 2026 Earnings
8-K SELL Aug 6, 2026 · 100% conf.
Q2 2026 Earnings
8-K SELLAug 6, 2026 · 100% conf.
1D
-1.04%
$29.91
Act: +2.51%
5D
-7.02%
$28.10
Act: +12.44%
20D
+3.87%
$31.39
Transcript text not available. View on SEC.gov →
2026 Q1 Q1 2026 Earnings
8-K May 7, 2026
Q1 2026 Earnings
8-KMay 7, 2026
2025 Q4 Q4 2025 Earnings
8-K Feb 26, 2026
Q4 2025 Earnings
8-KFeb 26, 2026
Compare TECX vs Leading Stocks
See how TECX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "TECX Tectonic Therapeutic Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.